Stockscreener 앱 받기
250.65
1.07%
2.66
시간 외 거래:
250.65
전일 마감가:
$247.99
열려 있는:
$249.16
하루 거래량:
193.09K
Relative Volume:
0.50
시가총액:
$6.27B
수익:
$2.58B
순이익/손실:
$-778.69M
주가수익비율:
-9.1712
EPS:
-27.33
순현금흐름:
$223.75M
1주 성능:
+4.01%
1개월 성능:
+15.74%
6개월 성능:
-23.15%
1년 성능:
-6.32%
1일 변동 폭
$247.53
$252.90
1주일 범위
$237.42
$254.82
52주 변동 폭
$211.43
$387.99
Bio Rad Laboratories Inc Stock (BIO) Company Profile
명칭
Bio Rad Laboratories Inc
전화
(510) 724-7000
주소
1000 ALFRED NOBEL DRIVE, HERCULES
BIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
250.65 | 6.27B | 2.58B | -778.69M | 223.75M | -27.33 |
|
ABT
Abbott Laboratories
|
134.11 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
103.63 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
391.81 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.28 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.02 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-08-28 | 개시 | Wells Fargo | Equal Weight |
| 2024-06-03 | 재개 | Jefferies | Hold |
| 2024-04-03 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-12-07 | 개시 | UBS | Buy |
| 2023-06-16 | 개시 | Wells Fargo | Overweight |
| 2022-12-07 | 개시 | RBC Capital Mkts | Outperform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-01-28 | 재확인 | Citigroup | Buy |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2018-10-17 | 개시 | Goldman | Buy |
| 2018-09-20 | 개시 | Morgan Stanley | Equal-Weight |
| 2018-02-16 | 다운그레이드 | CL King | Buy → Neutral |
| 2017-07-13 | 개시 | Wells Fargo | Outperform |
| 2017-06-28 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2017-01-18 | 개시 | Deutsche Bank | Hold |
| 2016-10-13 | 개시 | CL King | Buy |
| 2015-05-06 | 재확인 | Jefferies | Buy |
| 2009-12-18 | 개시 | Maxim Group | Buy |
| 2009-11-06 | 개시 | Jefferies & Co | Buy |
| 2009-07-17 | 개시 | Soleil | Buy |
| 2007-09-26 | 개시 | Banc of America Sec | Buy |
| 2007-02-23 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
모두보기
Bio Rad Laboratories Inc 주식(BIO)의 최신 뉴스
Transfection Reagents and Equipment Market | Driving Gene - openPR.com
Global Gene Expression Analysis Market | RNA Sequencing & PCR - openPR.com
Bio-Rad extends anti-idiotypic antibody and SpyCatcher Reagent ranges for bioanalysis and antibody drug development - Cambridge Network
Global Gel Electrophoresis Equipment Market Surges Amid Rising - openPR.com
DNA Extraction Kits Market Future Business Opportunities - openPR.com
Protein Engineering Market Fueled by AI, Genomics, - openPR.com
Immunohistochemistry Market Trends | Cancer Diagnosis & - openPR.com
How to Take Advantage of moves in (BIO) - news.stocktradersdaily.com
Global Genomics Market Surges Toward USD 115.4 Billion - openPR.com
Genetic Testing Market Surges Amid Rising Demand - openPR.com
Immunohematology Market Booming with Increased Blood Screening Initiatives | Bio-Rad Laboratories, Immucor Inc. - openPR.com
Protein Analyzers Market Projected to Rise with Increased Focus - openPR.com
Biopharmaceutical Processing Equipment and Consumables - openPR.com
One Step RT-qPCR Kits Market Top Companies StudyTakara Bio - openPR.com
Analysts Offer Insights on Healthcare Companies: Bio-Rad Laboratories (BIO) and Ramsay Health Care (OtherRMSYF) - The Globe and Mail
Horseradish Peroxidase Market Size, Share & Trends | Industry - openPR.com
Cell Biology Market Set to Experience Research Technology - openPR.com
5 Analysts Have This To Say About Bio-Rad Laboratories - Nasdaq
Wells Fargo Lowers Price Target for Bio-Rad Laboratories (BIO) | BIO Stock News - GuruFocus
Europe Chromatography Resins Market Size, Outlook 2031 by Key - openPR.com
Wells Fargo Adjusts Price Target for Bio-Rad (BIO), Maintains Eq - GuruFocus
Food Diagnostics Market | Rapid Pathogen & Contaminant - openPR.com
Clinical Laboratory Molecular Diagnostics for Infectious Disease Market Research 2025-2029: Biotechnology and Genomics Drive Advancements, Impact of Multiplex Assays in Diagnosis and Treatment - GlobeNewswire Inc.
Cancer Monoclonal Antibodies Market in 2025-2032 Detailed - openPR.com
Next Generation Sequencing Market to Witness Upsurge in Growth - openPR.com
bio-rad laboratories stock highlighted in cantor fitzgerald report - Investing.com Australia
bio-rad laboratories stock highlighted in cantor fitzgerald report By Investing.com - Investing.com South Africa
Laboratory Proficiency Testing Market Set to Witness - openPR.com
Minimal Residual Disease Testing Market Set to Witness - openPR.com
Enzyme Linked Immunosorbent Assay Market reached US$ 2.14 - openPR.com
Flow Cytometry Market Growth, Trends & Forecast 2025 | Global - openPR.com
Immunohistochemistry Market Detailed in New Research Report - openPR.com
Here’s Why Bio-Rad Laboratories (BIO) Traded Lower in Q1 - Insider Monkey
Global Microarray Market Size, Share & Growth Forecast - openPR.com
How DNA Sequencing Is Revolutionizing Cancer Genomics and Rare - openPR.com
Cell Viability Assays Market 2025 | Techniques, Applications & - openPR.com
High Resolution Melting Analysis Market Detailed in New - openPR.com
Gel Documentation Systems Market Projected to Witness Massive - openPR.com
Cell Signaling Market in 2025-2032 Detailed Study Analysis with - openPR.com
Neuroscience Antibodies and Assays Market Trends, Growth & - openPR.com
Bio-Rad Laboratories, Inc. (NYSE:BIO) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Learn to Evaluate (BIO) using the Charts - news.stocktradersdaily.com
Bio-Rad Laboratories (NYSE:BIO) Stock Rating Upgraded by Wall Street Zen - Defense World
Bio Rad Laboratories Inc (BIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bio Rad Laboratories Inc 주식 (BIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ENLOE COURTNEY C | EVP, General Counsel & Sec |
Apr 24 '25 |
Option Exercise |
0.00 |
186 |
0 |
196 |
| PINKSTON ARNOLD A | Director |
Apr 22 '25 |
Option Exercise |
0.00 |
308 |
0 |
308 |
| PEI MELINDA LITHERLAND | Director |
Apr 22 '25 |
Option Exercise |
0.00 |
308 |
0 |
308 |
| HINCKLEY GREGORY K | Director |
Apr 22 '25 |
Option Exercise |
0.00 |
308 |
0 |
308 |
| EDWARDS JEFFREY L | Director |
Apr 22 '25 |
Option Exercise |
0.00 |
308 |
0 |
308 |
| Crowley Michael | EVP, GBL Commercial Operations |
Mar 14 '25 |
Option Exercise |
159.32 |
3,000 |
477,960 |
11,171 |
| Crowley Michael | EVP, GBL Commercial Operations |
Mar 14 '25 |
Sale |
247.06 |
3,000 |
741,184 |
8,171 |
0.54%
1.82%
자본화:
|
볼륨(24시간):